Abstract:Rationale: Although stapled peptides offer a powerful solution to overcome the susceptibility of linear peptides to proteolytic degradation and improve their ability to cross membranes, an efficient and durable disease treatment strategy has not yet been developed due to the inevitable elimination of peptide inhibitors and rapid accumulation of target proteins. Methods: Herein we developed stapled peptide-based proteolysis-targeting chimeras (SP-PROTACs), that simultaneously exhibited improved cellular uptake and proteolytic stability attributed to the stapled peptides, and efficient target protein degradation promoted by the PROTACs. Based on the PMI peptide with dual specificity for both MDM2 and MDMX, a series of SP-PROTACs were designed. Results: Among them, the optimized SPMI-HIF2-1 exhibited similar binding affinity with MDM2 and MDMX but obviously higher helical contents, improved proteolytic stability, better cellular permeability, and a better pharmacokinetic profile compared with its linear counterpart. Importantly, SPMI-HIF2-1 could effectively kill cancer cells and inhibit tumor progression in subcutaneous and orthotopic colorectal cancer xenograft models through simultaneously promoting the atypical degradation of both MDM2 and MDMX and durable p53 activation. An FP-based binding assay and structural modeling analysis of the ternary complex suggested that SPMI-HIF2-1 simultaneously bound with the target protein and E3 ligase. Conclusion: Our findings not only provide a new class of anticancer drug candidates, but also bridge the gap and reduce the physical distance between peptides and PROTACs.

Turning Chiral Peptides into a Racemic Supraparticle to Induce the Self-Degradation of MDM2.

Chiral Protein Supraparticles for Tumor Suppression and Synergistic Immunotherapy: an Enabling Strategy for Bioactive Supramolecular Chirality Construction

Chirality-Mediated Polypeptide Micelles for Regulated Drug Delivery

A nano-predator of pathological MDMX construct by clearable supramolecular gold(I)-thiol-peptide complexes achieves safe and potent anti-tumor activity

Turing Milk into Pro-Apoptotic Oral Nanotherapeutic: De Novo Bionic Chiral-Peptide Supramolecule for Cancer Targeted and Immunological Therapy.

Tuning Supramolecular Chirality in Iodinated Amphiphilic Peptides Through Tripeptide Linker Editing

Peptide-Induced Self-Assembly of Therapeutics into a Well-Defined Nanoshell with Tumor-Triggered Shape and Charge Switch

Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression

Design of Murine Double Minute 2 Proteolysis Targeting Chimera Degraders with a Built-In Tumor-Targeting Ability

A Transformable Chimeric Peptide for Cell Encapsulation to Overcome Multidrug Resistance.

In-Tether Chiral Center Induced Helical Peptide Modulators Target P53-Mdm2/mdmx and Inhibit Tumor Growth in Stem-Like Cancer Cell

Chiral self-assembly of peptides: Toward the design of supramolecular polymers with enhanced chemical and biological functions

Enzyme-Mimetic, Cascade Catalysis-Based Triblock Polypeptide-Assembled Micelles for Enhanced Chemodynamic Therapy.

Sequential Assembled Chimeric Peptide for Precise Synergistic Phototherapy and Photoacoustic Imaging of Tumor Apoptosis

Chirality-Dependent Reprogramming of Macrophages by Chiral Nanozymes.

Supramolecular Chiral Self-Assembly of Peptides and Its Applications

Resurrecting a p53 peptide activator - An enabling nanoengineering strategy for peptide therapeutics

Homo-PROTAC Mediated Suicide of MDM2 to Treat Non-Small Cell Lung Cancer

Self-Assembly of Peptide Chiral Nanostructures with Sequence-Encoded Enantioseparation Capability.

A Potential MDM2 Inhibitor Formed by Restoring the Native Conformation of the p53 alpha-Helical Peptide on Gold Nanoparticles

Tumor-triggered transformation of chimeric peptide for dual-stage-amplified magnetic resonance imaging and precise photodynamic therapy.